Thyrocare Technologies Ltd
NSE:THYROCARE
ROE
Return on Equity (ROE) measures how effectively a company generates profit from shareholders` equity. It shows how much net income is earned for each dollar invested by shareholders.
Return on Equity (ROE) measures how effectively a company generates profit from shareholders` equity. It shows how much net income is earned for each dollar invested by shareholders.
Peer Comparison
| Country | Company | Market Cap | ROE | ||
|---|---|---|---|---|---|
| IN |
|
Thyrocare Technologies Ltd
NSE:THYROCARE
|
57.1B INR |
Loading...
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
96.8B USD |
Loading...
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
67.3B EUR |
Loading...
|
|
| US |
|
Cigna Corp
NYSE:CI
|
70.4B USD |
Loading...
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
26.5B EUR |
Loading...
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.1B EUR |
Loading...
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
22B USD |
Loading...
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.7B USD |
Loading...
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11B EUR |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.2B USD |
Loading...
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
10.3B USD |
Loading...
|
Market Distribution
| Min | -3 688.9% |
| 30th Percentile | 5.1% |
| Median | 11.1% |
| 70th Percentile | 16% |
| Max | 7 187.1% |
Other Profitability Ratios
Thyrocare Technologies Ltd
Glance View
Thyrocare Technologies Ltd. engages in provison of indepedent diagnostic and pathological laboratory services. The company is headquartered in Navi Mumbai, Maharashtra and currently employs 2,115 full-time employees. The company went IPO on 2016-05-09. The firm operates with a centralized processing laboratory (CPL) in Mumbai, India for esoteric tests, and regional processing laboratory in metro cities of India and other parts of Asia. The firm offers technologies, including Chemiluminescence Immunoassay (CLIA), Enzyme Linked Immunosorbent Assay (ELISA), High Performance Liquid Chromatography (HPLC), Capillary Electrophoresis (CE), Ion Selective Electrode (ISE), Fluorescence Flow Cytometry, Nephelometry, Photometry, Liquid Chromatography Mass Spectrometry (LC-MS), Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) and Cytogenetics. The firm offers various kinds of tests, such as Aarogyam X, Aarogyam XL, Aarogyam 1.1, Aarogyam 1.2 and Covid Antibody GT. The company also offers Thyroxine (T4), Triiodothyronine (T3), Thyroid-stimulating hormone and Complete Vitamin Profile tests.
See Also
ROE is calculated by dividing the Net Income by the Avg Total Equity.
The current ROE for Thyrocare Technologies Ltd is 26.9%, which is above its 3-year median of 16.8%.
Over the last 3 years, Thyrocare Technologies Ltd’s ROE has increased from 14.4% to 26.9%. During this period, it reached a low of 11.3% on Jun 30, 2023 and a high of 26.9% on Jan 1, 2026.
